The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

Background:The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway are currently in clinical development. It is likely that clinical testing of these agents will be in combination with standard therapies to harness the apoptotic potential of both the agents. To support this strategy, it has been widely observed that a number of chemotherapeutics stimulate the activation of several intracellular signalling cascades including Ras/RAF/MEK/ERK. The MEK1/2 inhibitor selumetinib has been shown to have anti-tumour activity and induce apoptotic cell death as a monotherapy.Methods:The aim of this study was to identify agents, which would be likely to offer clinical benefit when combined with selumetinib. Here, we used human tumour xenograft models and assessed the effects combining standard chemotherapeutic agents with selumetinib on tumour growth. In addition, we analysed tumour tissue to determine the mechanistic effects of these combinations.Results:Combining selumetinib with the DNA-alkylating agent, temozolomide (TMZ), resulted in enhanced tumour growth inhibition compared with monotherapies. Biomarker studies highlighted an increase in γH2A.X suggesting that selumetinib is able to enhance the DNA damage induced by TMZ alone. In several models we observed that continuous exposure to selumetinib in combination with docetaxel results in tumour regression. Scheduling of docetaxel before selumetinib was more beneficial than when selumetinib was dosed before docetaxel and demonstrated a pro-apoptotic phenotype. Similar results were seen when selumetinib was combined with the Aurora B inhibitor barasertib.Conclusion:The data presented suggests that MEK inhibition in combination with several standard chemotherapeutics or an Aurora B kinase inhibitor is a promising clinical strategy.

[1]  Rey-Huei Chen,et al.  Mps1 Phosphorylation by MAP Kinase Is Required for Kinetochore Localization of Spindle-Checkpoint Proteins , 2006, Current Biology.

[2]  E. Krebs,et al.  Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Ting,et al.  Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  W. May,et al.  Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Herlyn,et al.  The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel , 2008, Clinical Cancer Research.

[6]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[7]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[8]  Paul D. Smith,et al.  The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer , 2010, Clinical Cancer Research.

[9]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[10]  Jorge A. Almenara,et al.  Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. , 2011, Blood.

[11]  P. Dent,et al.  Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. , 2007, Cancer research.

[12]  Neal Rosen,et al.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. , 2005, Cancer cell.

[13]  P. Dent,et al.  Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. , 2008, Blood.

[14]  Ceri M. Wiggins,et al.  ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL , 2007, The EMBO journal.

[15]  R. Perez-soler,et al.  Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. , 2005, Cancer research.

[16]  S. Cook,et al.  Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.

[17]  G. Pagès,et al.  Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function , 2003, Oncogene.

[18]  G. Tzivion,et al.  Raf-1/MEK/MAPK Pathway Is Necessary for the G2/M Transition Induced by Nocodazole* , 2000, The Journal of Biological Chemistry.

[19]  H. Friedman,et al.  Temozolomide and treatment of malignant glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Paul D. Martin,et al.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.

[21]  S. Horwitz,et al.  Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. , 2001, Molecular pharmacology.

[22]  M. Scheid,et al.  Regulation of Bad Phosphorylation and Association with Bcl-xL by the MAPK/Erk Kinase* , 1999, The Journal of Biological Chemistry.

[23]  P. Dent,et al.  Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. , 2001, Molecular pharmacology.

[24]  A. Aplin,et al.  Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling , 2005, Oncogene.

[25]  P. LoRusso,et al.  Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Shi Yan,et al.  The MAP kinase pathway is required for entry into mitosis and cell survival , 2004, Oncogene.

[27]  L. Greene,et al.  Nerve Growth Factor (NGF) Down-regulates the Bcl-2 Homology 3 (BH3) Domain-only Protein Bim and Suppresses Its Proapoptotic Activity by Phosphorylation* , 2002, The Journal of Biological Chemistry.

[28]  K. Flaherty,et al.  Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. , 2010 .

[29]  R. Craig,et al.  MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol , 2004, Oncogene.

[30]  P. Dent,et al.  Sequence Dependent Exposure of Mammary Carcinoma Cells to Taxotere® and the MEK1/2 Inhibitor U0126 Causes Enhanced Cell Killing In Vitro , 2003, Cancer biology & therapy.

[31]  E. White,et al.  Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. , 2005, Cancer cell.

[32]  K. Cowan,et al.  Irradiation-induced G2/M checkpoint response requires ERK1/2 activation , 2007, Oncogene.

[33]  T. Guadagno,et al.  B-RafV600E signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells , 2008, Oncogene.

[34]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.